Document is current

Article History

Received: 24 February 2022

Accepted: 31 August 2022

First Online: 5 September 2022

Declarations

:

: Individual patient consent was not required for this study, according to Danish legislation. Access to patient records and data collection as part of the study was approved by The Region of Central Denmark and The Danish Data Protection Agency (reference number 1–16-02–406-21). According to Danish regulations an Ethical Committee approval was not required under Danish legislation and the study met the Declaration of Helsinki standards.

: Not applicable.

: Sarah Kelddal has nothing to disclose.Anne-Mette Hvas has no conflicts of interest regarding the present paper but has the following generel conflicts of interest: Speaker’s fees from CSL Behring, Boehringer-Ingelheim and Bayer and unrestricted research support from CSL Behring and Octapharma.Erik Lerkevang Grove has received speaker honoraria or consultancy fees from AstraZeneca, Alexion Pharma, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer, MSD, MundiPharma, Organon, Portola Pharmaceuticals, Lundbeck Pharma and Roche. He is an investigator in studies sponsored by AstraZeneca and has received unrestricted research grants from Boehringer Ingelheim.Henrik Birn reports speaker honoraria or consultancy fees from AstraZeneca, Vifor Pharma, Norvatis Healthcare, Alexion, MSD, Galapagos, NOVO Nordisk; Research grants from Vifor Pharma and Glaxo Smith Kline; and advisory membership with Kidney and Dialysis, Danish Health Authority, Augustinus Foundation and Helen and Ejnar Bjørnow Foundation.